Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran

Internal and Emergency Medicine

Volumn 7, Issue 5, 2012, Pages 447-452

  Talebi Bezmin Abadi, Amin ^a   Ghasemzadeh, Ali ^b   Taghvaei, Tarang ^c,d   Mobarez, Ashraf Mohabbati ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b MARQUETTE UNIVERSITY   (United States)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Tooba Clinic   (Iran)

Author keywords

Helicobacter pylori; Iran; Moxifloxacine; Treatment

Indexed keywords

ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IRAN; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRAN; MALE; MIDDLE AGED; OFLOXACIN; QUINOLINES; YOUNG ADULT;

EID: 84866552610     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0563-1     Document Type: Article

References (40)

1. O'Connor A, Gisbert J, McNamara D, O'Morain C (2010) Treatment of Helicobacter pylori infection 2010 Helicobacter 15: 46-52.
2. Mansour-Ghanaei F, YousefiMashhour M, Joukar F, Sedigh M, Bagher-Zadeh AH, Jafarshad R (2009) Prevalence of Helicobacter Pylori infection among children in Rasht, Northern Iran. Middle East J Dig Dis 1: 84-88.
3. Goldman C, Barrado A, Janjetic M, Balcarce N, CuetoRua E, Oshiro M et al (2006) Factors associated with H. pylori epidemiology in symptomatic children in Buenos Aires, Argentina. World J Gastroenterol 12: 5384-5388.
4. Douraghi M, Mohammadi M, Oghalaie A, Abdirad A, Mohagheghi MA et al (2008) dupA as a risk determinant in Helicobacter pylori infection. J Med Microbiol 57: 554-562.
5. Salehi Z, HalimiJelodar M, Rassa M, Ahaki M, Mollasalehi H, Mashayekhi F (2009) Helicobacter pylori cagA status and peptic ulcer disease in Iran. Dig Dis Sci 54: 608-613.
6. Megraud F (2004) H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53: 1374-1384.
7. Saberi-Firoozi M, Nejabat M (2006) Experiences with Helicobacter pylori treatment in Iran. Iran J Med Sci 31: 181-185.
8. Malekzadeh R, Derakhshan MH, Malekzadeh Z (2009) Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med 12: 576-583.
9. TalebiBezminAbadi A, MohabatiMobarez A, Taghvaei T, Wolfram L (2010) Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. Helicobacter 15: 505-509.
10. HaghiTomatari F, MohabbatiMobarez A, Amini M, Hosseini D, TalebiBezminAbadi A (2010) Helicobacter pylori resistance to metronidazole and clarithromycin in dyspeptic patients in Iran. IRCMJ 12: 409-412.
11. Fakheri H, Merat S, Hosseini V, Malekzadeh R (2004) Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 19: 89-93.
12. John Albert M, Al-Mekhaizeem K, Neil L, Dhar R et al (2006) High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. Aliment Pharmacol Ther 24: 1359-1366.
13. Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A et al (2005) A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 22: 45-49.
14. Zullo A, De Francesco V, Hassan C, Panella C, Morini S, Ierardi E (2006) Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study. Therapy 3: 251-254.
15. Kuei-Hsiang Hung, Bor-Shyang Sheu, Wei-Lun Chang, Hsiu-Mei Wu, Chin-Cheng Liu, Jiunn-Jong Wu (2009) Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 14: 61-65.
16. Graham DY, Abudayyeh S, El-Zimaity HM, Hoffman J, Reddy R, Opekun AR (2006) Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther 24: 845-850.
17. Nista EC, Candelli M, Zocco MA et al (2005) Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 21: 1241-1247.
18. Boyanova L, Gergova G, Knikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I (2008) Prevalence and evolution of Helicobacter pylori resistance to 6 antimicrobial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 60: 409-415.
19. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, Soussy CJ, Cambau E (2007) Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agent 29: 389-396.
20. Sherif M, Mohran Z, Fathy H, Rockabrand DM, Rozmajzl PJ, Frenck RW (2004) Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt. J Clin Microbiol 42: 4832-4834.
21. Watanabe Y, Aoyama N, Shirasaka D, Maekawa S, Kuroda K, Miki I et al (2003) Levofloxacin-based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 35: 711-715.
22. Gisbert JP, De La Morena F (2006) Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 23: 35-44.
23. Saad RJ, Schoenfeld P, Kim HM, Chey WD (2006) Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 101: 488-496.
24. Leszczynska K, Namiot A, Namiot Z, Leszczynska JK, Jakoniuk P, Chilewicz M, Namiot DB, Kemona A, Milewski R, Bucki R (2010) Patient factors affecting culture of Helicobacter pylori isolated from gastric mucosal specimens. Advances in medical sciences 55. doi: 10. 2478/v10039-010-0028-1.
25. Megraud F, Lehours P (2007) Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 20: 280-322.
26. Kusters JG, ArnoudVliet HM, Kuipers EJ (2006) Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 19: 449-490.
27. Clinical and Laboratory Standards Institute (CLSI) (2007) Performance standards for antimicrobial susceptibility testing; fifteenth information supplement. Wayne, PA.
28. Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F (2003) The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. Med Sci Monit 9: PI105-8.
29. Rafeey M, Ghotaslou R, Nikvash S, AshrafyHafez A (2007) Primary resistance in Helicobacter pylori isolated in children from Iran. J Infect Chemother 13: 291-295.
30. Rimbara E, Noguchi N, Tanabe M et al (2005) Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001. Clin Microbiol Infect 11: 307-311.
31. De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, Stoppino G et al (2007) Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 59: 783-785.
32. Falsafi T, Mobasheri F, Nariman F, Najafi M (2004) Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the Pediatric Medical Center of Tehran, Iran. J Clin Microbiol 42: 387-389.
33. Siavoshi F, Pourkhajeh AH, Merat S, Asl-Soleimani H, Heydarian E, Khatibian M et al (2000) Susceptibility of various strains of Helicobacter pylori to selected agents. Arch Iran Med 3: 60-63.
34. FallahiGh H, Maleknejad Sh (2007) Helicobacter pylori culture and antimicrobial resistance in Iran. Iran J Pediatr 74: 127-130.
35. Khashei R, Shojaei H, Adibi P, Shavakhi A, Aslani MM, Naser AD (2008) Genetic diversity and drug resistance of Helicobacter pylori strains in Isfahan, Iran. Iran J Basic Med Sci 11: 174-182.
36. Koletzko S, Richy F, Bontems P, Crone J, Kalach N, Monteiro ML, European Pediatric Task Force on Helicobacter pylori et al (2006) Prospective multicenter study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 55: 1711-1716.
37. Street ME, Caruana P, Caffarelli C, Magliani W, Manfredi M, Fornaroli F et al (2001) Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome. Arch Dis Child 84: 419-422.
38. Boyanova L, Markovska R, Yordanov D, Marina M, Ivanova K, Panayotov S, Gergova G, Mitov I (2009) High prevalence of virulent Helicobacter pylori strains in symptomatic Bulgarian patients. Diagn Microbiol Infect Dis 6: 374-380.
39. Agudo S, Peerez-Perez G, Alarcon T, lopez-Brea M (2010) High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol 48: 3703-3707.
40. Boyanova L, Nikolov R, Lazarova E, Gergova G et al (2006) Antibacterial resistance in Helicobacter pylori strains isolated from Bulgarian children and adult patients over 9 years. J Med Microbiol 55: 65-68.